Research Overview
· Last Reviewed May 3, 2026· PSI Editorial Board· IndependentCan Peptides Help Me Live Longer?
The honest map across 8 longevity domains: what's been studied, what's reached human trials, and what nobody has confirmed yet.
WHAT'S YOUR PRIMARY INTEREST?
Domain
Animal Studies
Human Trials
Mitochondrial dysfunction
Barth syndrome, primary mitochondrial myopathy
Cardiac aging
Heart failure, age-related cardiac decline
Skin aging
Wrinkles, photodamage, firmness
Telomere maintenance
Cellular senescence, replicative aging
Metabolic aging
Insulin resistance, T2D risk, exercise capacity
Neuroprotection
Cognitive decline, neurodegeneration
Pineal / sleep regulation
Age-related sleep architecture
Cellular cytoprotection
Apoptosis prevention, oxidative stress
How counts are scaled → · Tap any row to see the studies →
Quick Answer
Longevity peptides are not a treatment for aging. None has FDA approval for general healthspan extension or anti-aging use. Six compounds get the most attention. Here is what each one's evidence actually supports.
SS-31 (sold as Forzinity since September 2025) is the only mitochondria-targeted peptide with FDA approval. The approval is narrow. It covers Barth syndrome, an ultra-rare pediatric mitochondrial disease affecting about 150 individuals in the United States. Phase 3 trials in heart failure missed primary endpoints. Phase 3 trials in primary mitochondrial myopathy and dry age-related macular degeneration are ongoing. SS-31 is a real mitochondrial therapeutic for one specific disease, not a longevity drug.
GHK-Cu has the deepest controlled human evidence on this list, but only for one application. Topical skin care. Multiple controlled trials show wrinkle reduction, improved skin firmness, and minor wound healing when applied as a cream. The compound modulates over 4,000 genes in fibroblast cultures. Whether topical effects translate to systemic anti-aging via injection has not been tested in controlled human studies.
Epitalon is the most-studied peptide bioregulator from the Khavinson research program in Russia. Animal studies suggest telomerase activation. The strongest single piece of human evidence is a 2003 study from the same Russian research group reporting reduced mortality in elderly patients receiving Epitalon over six years. The trial was small, single-group, and has not been independently replicated outside that institutional cluster.
MOTS-c, Humanin, and Pinealon are preclinical. MOTS-c is a peptide encoded inside the mitochondrial genome itself, acting like an exercise mimetic in animal models. Plasma levels decline with age. Zero interventional human trials. Humanin is another mitochondrial-derived peptide, cytoprotective in cell culture and animal models. Plasma levels decline with age. Zero published human trials. Pinealon is a Khavinson-program tripeptide studied for neuroprotection in Russian research; the Western controlled-trial literature does not exist.
The honest framing: the underlying biology of mitochondrial decline, telomere shortening, and cellular senescence is real and worth tracking. The peptides marketed for longevity address those mechanisms in animal models. The leap from rodent evidence to validated human healthspan extension has not happened for any compound on this page. SS-31's Barth syndrome approval validates the mitochondrial-targeting mechanism for a specific disease, not for general aging.
SS-31 vs MOTS-c
Two mitochondrial peptides, two completely different mechanisms
SS-31 acts on mitochondrial structure. It is a synthetic four-amino-acid peptide that crosses the cell membrane and embeds in the inner mitochondrial membrane. There it binds cardiolipin via electrostatic and hydrophobic interactions. Cardiolipin is a phospholipid that stabilizes the cristae, the convoluted folds where the electron transport chain is anchored. When cardiolipin is damaged, cristae fragment, ATP production drops, and reactive oxygen species rise. SS-31 stabilizes the structural foundation of mitochondrial energy production. The mechanism is structural protection, not metabolic substrate provision. SS-31 received FDA accelerated approval in September 2025 for Barth syndrome and has the deepest human clinical trial portfolio of any longevity-related peptide.
MOTS-c acts on mitochondrial signaling. It is a 16-amino-acid peptide encoded inside the mitochondrial genome itself. That is unusual: most peptide hormones are encoded by the nuclear genome. MOTS-c functions as a circulating signaling molecule: produced inside mitochondria, secreted into plasma, and acting at distant tissues to activate AMPK. AMPK is the cellular energy sensor that orchestrates glucose uptake, fatty acid oxidation, and mitochondrial biogenesis. The mechanism is metabolic activation, not structural protection. MOTS-c has zero interventional human trials. Plasma levels decline with age, and lower levels correlate with metabolic disease in observational studies.
Many longevity protocols stack the two compounds, citing complementary mechanisms (structural protection plus functional activation). The stacking rationale is mechanistic: SS-31 keeps mitochondrial machinery intact while MOTS-c signals the machinery to work harder. The rationale sounds reasonable. No controlled study has tested the combination in humans for any longevity-related endpoint. The Phase 2/3 trials supporting SS-31's FDA approval used SS-31 alone in Barth syndrome populations. The MOTS-c animal-model literature uses MOTS-c alone. The clinical evidence supporting either compound for general longevity (as opposed to disease-specific indications) is absent for both.
Both compounds are research-grade for general longevity use. SS-31's narrow Barth syndrome approval validates the cardiolipin-stabilization mechanism for one specific genetic disease, not for healthspan extension in healthy adults. MOTS-c's preclinical evidence is real but has not crossed the human-trial threshold. PSI's reading on longevity stacking: the underlying mitochondrial biology is genuinely interesting and worth tracking. Anyone framing the SS-31 plus MOTS-c stack as scientifically validated for healthspan extension is reading further into the data than the data supports.
The Khavinson institutional cluster: why some longevity peptides have only one country's research
Epitalon, Pinealon, and what independent replication looks like
Two of the six compounds on this page (Epitalon and Pinealon) come from the same research program. That program is the St. Petersburg Institute of Bioregulation and Gerontology, under Vladimir Khavinson. The Khavinson program has been active for more than four decades. It has developed approximately 20 short peptides collectively called peptide bioregulators. The published literature is real, peer-reviewed, and substantial. The structural concern is that almost all of it comes from one institutional ecosystem.
Validated drugs in modern medicine accumulate evidence across multiple independent research groups, institutions, and countries. The clinical trials supporting GLP-1 receptor agonists like semaglutide come from research programs across many countries. Denmark, the United States, the United Kingdom, Germany, and dozens of other contributing institutions. The clinical trials supporting SS-31 originated at IRCM Montreal and Cornell. They advanced through Stealth BioTherapeutics and were tested across multiple US and European trial sites. Independent replication is how scientific consensus forms. It is not optional.
The Khavinson program proposes that short peptides bind specific DNA promoter regions and modulate gene expression through that direct binding. This is an unconventional mechanism. It has not been independently replicated by mainstream molecular biology programs at the scale that would be expected if the mechanism were broadly correct. Whether the mechanism is correct or not, the evidence-quality concern stands: claims of clinical efficacy supported primarily by a single institutional cluster do not meet the same evidence bar as claims supported by independent multi-center research.
This does not mean the Khavinson research is incorrect. It means the evidence is concentrated, not distributed, and independent replication is the missing layer needed for confident clinical claims. PSI's reading: Epitalon has the strongest single piece of human longevity-outcome data on this page (the 2007 Khavinson 12-year mortality study). That data still falls short of the trial standards that would support a confident lifespan-extension claim, because the same research group developed the compound and conducted the trial. Pinealon has even thinner human evidence. For both compounds, the meaningful next step is independent Western controlled trials. Until those exist, both are research-grade peptides with interesting biology and unproven clinical effects.
The Compounds, Ranked by Evidence
Ordered by strength of controlled human data, not popularity.
Of the 6 most-discussed peptides for longevity, one (SS-31, sold as Forzinity since September 2025) holds FDA approval for Barth syndrome only. One (GHK-Cu) has decades of controlled human evidence for topical skin applications. The other four sit at preclinical or single-region human evidence. Here is what each one's trials and animal studies actually show.
SS-31 (Elamipretide / Forzinity)
First FDA-approved mitochondria-targeted therapeutic. Approved September 2025 for Barth syndrome only (~150 US patients). Heart failure trials missed primary endpoints. Not approved for general longevity.
Counts are PubMed-indexed papers and registered clinical trials. Scale: Strong 10+, Moderate 4–9, Limited 1–3, None 0. Methodology →
| Domain | Animal Studies | Human Trials |
|---|---|---|
Barth syndrome ultra-rare pediatric mitochondrial disease, ~150 US patients | 8 Improved cardiolipin maturation, restored ATP production, and normalized cristae structure reported in TAFAZZIN-deficient cell models and animal models. | 2 TAZPOWER Phase 2/3 crossover (n=12) part 1 primary endpoints not met; open-label extension at 36 weeks supported sustained muscle-strength improvement. FDA accelerated approval September 19, 2025 (Forzinity, Stealth BioTherapeutics). |
Heart failure with reduced ejection fraction HFrEF | 12 Improved cardiac energetics, reduced left ventricular remodeling, and reduced ROS reported in animal heart failure models. | 2 PROGRESS-HF Phase 2 (n=71, 28 days subcutaneous): primary endpoint of LVESV change not met. Earlier IV trial (n=28) showed dose-related LV volume reductions but did not progress to Phase 3. |
Heart failure with preserved ejection fraction HFpEF | 6 Improved diastolic function and cardiac energetics reported in HFpEF animal models. | 2 Phase 2 trials NCT02814097 and NCT02914665 completed; primary endpoints not met. Mechanistic signals on diastolic parameters did not reach statistical significance. NCT02814097 |
Primary mitochondrial myopathy PMM | 5 Improved exercise performance and skeletal muscle bioenergetics reported in disease-model rodents. | 2 MMPOWER Phase 2 showed exercise improvement after 5 days of treatment with no safety concerns. NuPOWER Phase 3 (NCT05162768) ongoing; results pending. NCT05162768 |
Dry age-related macular degeneration dry AMD | 4 Reduced photoreceptor loss and retinal protection reported in mouse models of retinal degeneration. | 1 ReNEW Phase 3 trial ongoing. Prior Phase 2 ReCLAIM trials reported retinal function improvements; primary endpoints in pivotal Phase 3 readouts pending. ReNEW Phase 3 |
Acute kidney injury ischemia-reperfusion | 9 Reduced tubular injury and improved kidney function reported in animal models of ischemia-reperfusion AKI. | 1 Phase 1 safety trial completed. Efficacy data limited; no Phase 3 program for AKI as of 2026. |
GHK-Cu
Decades of controlled human evidence, exclusively for topical skin application. Modulates 4,000+ genes in fibroblast cultures. Systemic injectable use is preclinical.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Skin aging wrinkles, firmness, photodamage | 8 Improved collagen production and skin remodeling indicators reported in animal models. | 6 Multiple controlled topical trials reported reduced fine lines, improved firmness, and photodamage repair. All studies used topical (cream) administration. Leyden 2002 |
Topical wound healing cutaneous repair | 6 Faster wound closure and improved tissue regeneration reported in animal models of cutaneous injury. | 3 Topical application studies reported faster wound closure and reduced scarring. Topical only. |
Hair restoration androgenetic alopecia | 4 Increased hair follicle size and growth indicators reported in animal models. | 2 Topical formulations reported improved hair density in small controlled trials. |
Systemic tissue repair internal organs, deep tissue | 5 Effects on inflammatory markers and gene expression (>4,000 genes modulated) reported in animal models. | 0 None published. All controlled human trials of GHK-Cu used topical, not systemic, administration. |
Joint and musculoskeletal tendon, cartilage | 2 Limited animal-model data on direct musculoskeletal application. | 0 None published. |
Epitalon
Strongest single human longevity-outcome data on this page (2007 Khavinson 12-year mortality study), with the caveat of single-research-group concentration. Not independently replicated.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Telomerase activity cell-culture and animal models | 6 Telomerase activation and telomere elongation reported in human somatic cell cultures and aged rodent models. | 0 No published controlled human telomere-length trials of synthetic Epitalon outside the Khavinson research cluster. |
Mortality reduction (elderly cohort) long-term follow-up | 3 Lifespan extension reported in aged rodent studies from Khavinson-program research. | 1 Khavinson 2007 12-year follow-up in elderly patients reported reduced relative mortality risk vs controls. Single research group; small sample; not independently replicated. |
Pineal and circadian regulation melatonin, sleep | 4 Effects on melatonin signaling and circadian rhythm parameters reported in rodent models. | 0 None published in Western peer-reviewed literature. |
Retinal protection retinitis pigmentosa | 2 Limited preclinical retinal-protection data from Khavinson-program studies. | 1 Small Russian observational study in retinitis pigmentosa patients; not controlled or independently replicated. |
General aging biomarkers oxidative stress, immune function | 5 Improvements in oxidative stress markers and immune function reported in aged rodents. | 0 None published as controlled trials. |
MOTS-c
Mitochondrial-genome encoded, AMPK activator. Strong preclinical exercise-mimetic story. Plasma levels decline with age. Zero interventional human trials.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Insulin sensitivity and glucose homeostasis metabolic regulation | 12 Improved insulin sensitivity, reversed weight gain, and normalized glucose handling reported in multiple rodent models including high-fat-diet-induced T2D. | 0 Zero interventional trials. Multiple observational studies show plasma MOTS-c levels reduced in T2D patients vs healthy controls. |
Exercise capacity skeletal muscle metabolism | 6 Increased running endurance and improved skeletal muscle metabolism reported in aged mouse models. | 0 Zero interventional trials. Observational data shows plasma MOTS-c levels rise during exercise in healthy adults. |
Age-related metabolic decline aging biomarkers | 8 Reversal of age-associated insulin resistance and metabolic dysfunction reported in aged rodent models. | 0 Plasma MOTS-c levels decline with age in human cohort studies. Correlative, not interventional. |
Obesity diet-induced and pediatric | 5 Reduced body weight and improved metabolic markers reported in diet-induced obesity rodent models. | 0 Lower plasma MOTS-c reported in obese vs lean adults and adolescents in cohort studies. |
Cardiovascular and endothelial function vascular aging | 4 Improvements in endothelial function and reductions in atherosclerotic markers reported in animal models. | 0 Coronary endothelial dysfunction associated with reduced plasma MOTS-c in observational studies. |
Humanin
Mitochondrial-derived peptide, cytoprotective signaling. Plasma levels decline with age. Strong animal-model neuroprotection signal. Zero published human trials.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Neuroprotection (Alzheimer's models) amyloid-beta toxicity, cognitive decline | 14 Reduced amyloid-beta-induced neuronal cell death and improved cognitive performance reported in rodent AD models and cell culture. | 0 Zero interventional trials. Observational data shows lower humanin levels in Alzheimer's patients vs age-matched controls. |
Cardiac ischemia and infarct ischemia-reperfusion injury | 8 Reduced infarct size, improved cardiac function, and reduced apoptosis reported in rodent ischemia-reperfusion models. | 0 Zero interventional trials. Plasma humanin altered in MI patients in observational studies. |
Metabolic regulation insulin signaling, T2D | 6 Improved insulin sensitivity and glucose handling reported in diabetic rodent models. | 0 Plasma humanin levels reduced in T2D patients in cohort studies. |
Lifespan extension model organisms | 4 Humanin analog HNG extended lifespan in mice (Yen 2020). Plasma humanin declines with age. | 0 Plasma humanin levels decline with age in human cohort studies. Observational only. |
Cellular cytoprotection apoptosis prevention | 10 Suppression of Bax-mediated apoptosis demonstrated across multiple cell types and animal injury models. | 0 None published. |
Pinealon
Khavinson-program tripeptide. Russian institutional research cluster. Animal-model neuroprotection. No Western controlled human trials.
| Domain | Animal Studies | Human Trials |
|---|---|---|
Neuroprotection oxidative stress, neural injury | 8 Improved cognitive performance and reduced oxidative damage reported in aged rodent models and cell culture. Arutjunyan 2012 | 0 No published controlled trials in Western peer-reviewed literature. |
Cognitive aging memory, learning | 5 Improvement on aged-rat memory benchmarks reported in Khavinson-program studies. | 0 None published as controlled trials. |
Pineal and sleep regulation circadian, melatonin | 3 Effects on melatonin signaling reported in rodent models. | 0 None published. |
Developmental neuroprotection prenatal injury models | 2 Protection against prenatal hyperhomocysteinemia-induced injury reported in rat offspring. Arutjunyan 2012 | 0 None published. |
What's Marketed vs What's Studied
5 common claims, corrected.
“SS-31 is FDA-approved as a longevity peptide.”
SS-31 (Forzinity) received FDA accelerated approval in September 2025 for Barth syndrome only. Approval is for adult and pediatric patients with Barth syndrome weighing at least 30 kg. Heart failure trials missed primary endpoints. Approval is narrow and indication-specific, not a longevity claim.
“Epitalon extends human lifespan.”
The strongest human evidence is a 2007 Khavinson study reporting reduced 12-year mortality in elderly patients. The trial was small, single-group, and has not been independently replicated. Animal data suggests telomerase activation but does not validate a human lifespan claim.
“MOTS-c works as an exercise mimetic in humans.”
MOTS-c animal studies show exercise-mimetic effects via AMPK activation. No interventional human trial has been published. Observational data showing plasma MOTS-c rises during exercise and declines with age is correlation, not interventional evidence.
“Khavinson peptide bioregulators are scientifically validated.”
The Khavinson research program is genuinely longstanding and produces peer-reviewed work, but the evidence base is concentrated in a single institutional cluster (St. Petersburg Institute of Bioregulation and Gerontology). Independent replication outside that cluster is sparse, which is a meaningful evidence-quality concern.
“Topical GHK-Cu effects translate to systemic injectable longevity benefits.”
GHK-Cu's controlled human evidence is exclusively topical. Whether injected systemic GHK-Cu delivers comparable healthspan benefits has not been tested in controlled human trials. The 4,000-gene-modulation data comes from fibroblast cell cultures, not whole-body administration.
If Considering Use, Here Is How to Be Safe
How to evaluate sources, verify quality, and find qualified physicians.
Work with a licensed physician familiar with mitochondrial biology and aging research.
Avoid clinics whose primary business is selling peptides. Look for physicians with backgrounds in functional medicine, cardiology, or anti-aging research who can evaluate whether peptides are appropriate for the situation.
SS-31 (Forzinity) is FDA-approved only for Barth syndrome.
Off-label prescribing for general longevity is not currently supported by FDA-approved indications. Insurance does not cover off-label use. Direct-pay pricing for Forzinity is substantial.
Compounding pharmacies must be licensed by the state pharmacy board.
503A pharmacies prepare patient-specific compounds; 503B outsourcing facilities prepare office-use stock. Both require active state licensure. Verify before any prescription is filled.
Demand third-party HPLC purity testing.
Reputable compounding pharmacies provide certificates of analysis on request. If a supplier cannot produce one, that is the answer.
Watching and waiting is a legitimate option for any compound at preclinical evidence depth.
Validated healthspan interventions (Mediterranean dietary patterns, structured resistance training, sleep quality, social connection) have decades of trial evidence. Peptides at preclinical evidence depth do not yet. There is no penalty for waiting on stronger human data.
The regulatory landscape for longevity peptides is dynamic. SS-31 received FDA accelerated approval in September 2025 as the first mitochondria-targeted therapeutic, for Barth syndrome only. Continued approval is contingent on confirmatory trial data. Phase 3 trials of SS-31 in primary mitochondrial myopathy (NuPOWER, NCT05162768) and dry age-related macular degeneration (ReNEW) are ongoing. Both may extend the evidence base. The other compounds on this page have no FDA-approved indications. Regulatory status can change as new safety data is submitted, sponsors pursue formal approval pathways, or court rulings reshape FDA compounding authority. PSI tracks these developments and updates this page as material changes occur.
Find a verified physician
PSI's directory only lists physicians who have passed a five-gate verification process: state board active, no disciplinary actions, peptide-category competency, transparent pricing, and patient outcome documentation.
Browse the directoryLearn about the verification process →Common Questions
Is SS-31 (Forzinity) FDA-approved for longevity?
No. SS-31, sold as Forzinity by Stealth BioTherapeutics, received FDA accelerated approval in September 2025 for Barth syndrome only. The disease is an ultra-rare pediatric mitochondrial condition affecting about 150 individuals in the United States. The approval is for adult and pediatric patients with Barth syndrome weighing at least 30 kilograms. The mechanism (cardiolipin stabilization in the inner mitochondrial membrane) is plausibly relevant to broader mitochondrial dysfunction associated with aging. But Phase 2 and Phase 3 trials in heart failure (PROGRESS-HF, NCT02814097) did not meet primary endpoints. A primary mitochondrial myopathy Phase 3 trial (NuPOWER) and a dry age-related macular degeneration Phase 3 trial (ReNEW) are ongoing. As of 2026, SS-31 has FDA approval only for Barth syndrome. Use for general longevity or anti-aging is off-label and not supported by interventional human trial data.
Does Epitalon actually extend lifespan?
The strongest piece of human evidence cited for Epitalon's lifespan effect is a 2007 study by the Khavinson research group in St. Petersburg, Russia. Elderly patients receiving Epitalon and Thymalin over a 12-year follow-up showed reduced mortality compared to controls. The trial was small, conducted by the same research group that developed the compound, and has not been independently replicated by Western research institutions. In animal studies, Epitalon administration to aged rodents has been associated with telomerase activation, modest lifespan extension, and improvements in age-related markers. The animal evidence base is more substantial than the human evidence. The honest framing: Epitalon has the strongest human longevity-outcome data of any compound in this category. That data still falls well short of the trial standards that would support a confident claim of lifespan extension.
What's the difference between SS-31 and MOTS-c if both target mitochondria?
Different mechanisms, complementary effects. SS-31 is a synthetic four-amino-acid peptide that binds cardiolipin in the inner mitochondrial membrane and physically embeds in the membrane to stabilize the cristae. The mechanism is structural protection. SS-31 is FDA-approved (for Barth syndrome) and has the deepest human clinical trial portfolio of any longevity-related peptide. MOTS-c is a 16-amino-acid peptide encoded inside the mitochondrial genome itself. That makes it one of the first peptide hormones encoded outside the nuclear genome. It functions as a circulating signaling molecule that activates AMPK, the cellular energy sensor. The mechanism is metabolic activation. MOTS-c has zero interventional human trials. Many longevity protocols stack the two for complementary mechanisms (structural plus functional). The stacking rationale is mechanistic. No controlled study has tested the combination in humans.
Are Khavinson peptide bioregulators (Epitalon, Pinealon) clinically validated?
The evidence base for Khavinson peptide bioregulators is concentrated in a single institutional ecosystem. That ecosystem is the St. Petersburg Institute of Bioregulation and Gerontology and affiliated Russian research groups. This is a meaningful evidence-quality concern. Validated drugs in modern medicine accumulate evidence across multiple independent research groups, institutions, and countries. The Khavinson program proposes that short peptides bind specific DNA promoter regions and modulate gene expression. This is an unconventional mechanism. It has not been independently replicated by mainstream molecular biology programs at the scale that would be expected if the mechanism were broadly correct. The published animal-model literature reports neuroprotection, immune modulation, and aging-related improvements across multiple Khavinson-program peptides. The Western peer-reviewed controlled-trial literature for these compounds is very limited. The evidence is concentrated, not distributed, and independent replication is the missing layer.
Can topical GHK-Cu deliver longevity benefits, or do I need to inject it?
The controlled human evidence for GHK-Cu is exclusively topical. Multiple studies dating to the 1990s show wrinkle reduction, improved skin firmness, accelerated topical wound healing, and reduction in photodamage. All of those studies used GHK-Cu applied as a cream or topical formulation. The compound modulates over 4,000 genes in fibroblast cell cultures (Pickart, Vasquez-Soltero, Margolina 2012). Whether systemic injection delivers comparable longevity benefits is unproven in controlled human trials. Animal model data on injected GHK-Cu suggests effects on tissue repair, gene expression, and inflammatory pathways. None of those animal findings have been validated in interventional human studies. The honest framing for GHK-Cu in a longevity context: topical evidence is strong and dermatologically relevant. It does not automatically extend to systemic anti-aging via injection.
Medical Disclaimer
This content is for educational and informational purposes only and does not constitute medical advice. The information presented reflects published research as indexed by PSI and should not be used to make treatment decisions. Always consult a qualified healthcare provider before starting, stopping, or modifying any treatment.